Summary
Background Erlotinib is an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). Vinorelbine, a vinca alkaloid, interferes with microtubule assembly inhibiting mitosis during metaphase. Both drugs are commonly used as single agents in the treatment of advanced non small cell lung cancer (NSCLC). Given their efficacy in NSCLC and their non-overlapping toxicity profile, we conducted a phase I study of erlotinib and vinorelbine to establish the feasibility and safety of the combination and to determine the maximum tolerated dose (MTD). Patients and methods Patients with advanced solid tumors were treated with vinorelbine intravenously on day 1 and 8 and erlotinib orally daily on a 21 day schedule. The dose levels of vinorelbine/erlotinib were 25 mg/m2/100 mg, 25/150 and 30/150. Results Sixteen patients were enrolled. Five patients were chemo-naïve; 11 had one prior therapy. The majority of patients had NSCLC (n = 7). Dose limiting toxicities included febrile neutropenia (4 patients) and grade 5 infection (1 patient). Non-hematologic grade 3/4 toxicities included diarrhea, hypokalemia, infection, dyspnea and mucositis. Of 12 patients assessable for radiologic response, there were no objective responses; eight had stable disease. Conclusions (1) The MTD was vinorelbine 25 mg/m2 day 1 and 8 with erlotinib 100 mg/day every 21 days. (2) The combination was associated with high rate of febrile neutropenia (25%). (3) Due to subsequent data demonstrating a lack of efficacy of erlotinib in combination with platinum doublets in advanced NSCLC, this combination has not been explored further.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Cancer Society (2006) Cancer facts and figures 2006. Available at http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Statistics_2006_Presentation.asp. Accessed on December 2006
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909
Johnson D, Zhu J, Schiller J et al (1999) E1594-A randomized phase III trial in metastatic non-small cell lung cancer (NSCLC)-outcome of PS 2 patients (Pts): An eastern cooperative group trial (ECOG). (Meeting abstract). ASCO, Abstract 1779
Gridelli C, Perrone F, Nelli F et al (2001) Quality of life in lung cancer patients. Ann Oncol 12:S21–25
Gridelli C, Perrone F, Gallo C et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The multicenter Italian lung cancer in the elderly study (MILES) Phase III randomized trial. J Natl Cancer Inst 95:362–372
Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol 19:183–232
Genentech (2005) Tarceva® Prescribing Information. Available at http://www.gene.com/gene/products/information/oncology/tarceva/insert.jsp. Accessed on December 2006
Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132
Gatzemeier UP, Szczesna A, Kaukel A, Roubec E, Brennscheidt J, DeRosa U, Mueller F, von Pawel J (2004) Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer. ASCO, New Orleans
Giaccone G, Herbst RS, Manegold C et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 22:777–784
Herbst RS, Giaccone G, Schiller JH et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22:785–94
Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899
Scagliotti G, Rossi A, Novello S et al (2004) Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 22:7081:2004
Kajita J, Kuwabara T, Kobayashi H et al (2000) CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 28:1121–1127
Lilenbaum RC, Herndon JE II, List MA et al (2005) Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 23:190–196
Tester WJ, Stephenson P, Langer CJ et al (2004) ECOG 1599: Randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22:7055
Langer COK, Ross H et al (2005) Xyotax/carboplatin vs. paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy naïve advanced non small cell lung cancer (NSCLC): the STELLAR 2 phase III study. Lung Cancer 49(2):S36
Lilenbaum R, Axerold R, Thomas S et al (2006) Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. ASCO Meeting Abstracts 24:7022
Acknowledgement
We acknowledge the data management support of Gina Guillaume, Jun Lauder and Janet LaPointe.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported in part by University of California Davis Cancer Center Support Grant, Genentech and Glaxo-Smith Kline.
Rights and permissions
About this article
Cite this article
Davies, A.M., Ho, C., Hesketh, P.J. et al. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Invest New Drugs 25, 351–355 (2007). https://doi.org/10.1007/s10637-007-9045-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-007-9045-8